Aditxt, Inc. Operating Lease, Liability, Current
Aditxt, Inc. (ADTX) had Operating Lease, Liability, Current of $638.57 thousand as of 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-05-20
- 2026-03-31: Operating Lease, Liability, Current $638.57K.
- 2025-12-31: Operating Lease, Liability, Current $808.18K.
- 2025-09-30: Operating Lease, Liability, Current $641.44K.
- 2025-06-30: Operating Lease, Liability, Current $693.61K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-03-31 | $638.57K 10-Q · filed 2026-05-20 |
| 2025-12-31 | $808.18K 10-Q · filed 2026-05-20 |
| 2025-09-30 | $641.44K 10-Q · filed 2025-11-18 |
| 2025-06-30 | $693.61K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $688.47K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $683.35K 10-K · filed 2026-03-31 |
| 2024-09-30 | $678.33K 10-Q · filed 2024-11-18 |
| 2024-06-30 | $734.79K 10-Q · filed 2024-08-19 |
| 2024-03-31 | $900.98K 10-Q · filed 2024-05-20 |
| 2023-12-31 | $999.94K 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.08M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.10M 10-Q · filed 2023-08-14 |
| 2022-12-31 | $1.09M 10-K · filed 2024-04-16 |
| 2021-09-30 | $1.02M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $906.66K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $393.73K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $391.22K 10-Q · filed 2021-11-15 |
| 2020-09-30 | $326.90K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |